Analysıs of Urınary Albumın and Urınary Synaptopodın Levels in Type 2 Dıabetes Mellıtus Subjects
AbstractHyperglycemia from diabetes mellitus affects many body organs and interferes with normal function. Kidney function decreased in approximately one-third of patients with diabetes mellitus before the development of albuminuria. The purpose of this study was to analyze differences in urine albumin and urine synaptopodin levels in type 2 diabetes mellitus (T2DM) and non-DM subjects, differences in urine synaptopodin levels in T2DM subjects with and without nephropathy, to analyze the correlation between urine albumin and urine synaptopodin in T2DM subjects and the cut-off analysis of sensitivity and specificity of urinary synaptopodin in diagnosing diabetic nephropathy. A sample of 60 subjects comprised 40 T2DM subjects and 20 non-DM subjects. Urinary synaptopodin levels were examined using the ELISA method, and albuminuria levels using the immunoturbidimetric method. Based on statistical analysis, the results showed that there were differences in urine albumin levels in T2DM and non-DM subjects (p*= < 0.001), there were differences in urine synaptopodin levels in T2DM and non-DM subjects (p*= < 0.001), there were no differences in urine synaptopodin levels with and without nephropathy in T2DM subjects (p*= 0.090), a relationship was found between urine albumin and urinary synaptopodin in T2DM subjects (p*= 0.048, r= 0.314) and the cut off of urinary synaptopodin in diagnosing nephropathy was ³0.39 ng/mL, sensitivity 64.7% and specificity 56.5%. We recommend further prospective studies with larger sample sizes to compare urinary synaptopodin levels and microalbuminuria (MAU) as markers for early detection of DN in T2DM subjects.
American Diabetes Association (2021). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes care, 44(Suppl 1), S15–S33. https://doi.org/10.2337/dc21-S002
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020). Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules (Basel, Switzerland), 25(8), 1987. https://doi.org/10.3390/molecules25081987
Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. Avicenna Journal of Medicine, 10(4), 174–188. https://doi.org/10.4103/ajm.ajm_53_20
Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. (2020). Type 2 Diabetes and its Impact on the Immune System. Current diabetes reviews, 16(5), 442–449. https://doi.org/10.2174/1573399815666191024085838
Chen Z, Zhao Z, Wang J. (2019). Study on the clinical value of urinary synaptopodin in diabetic nephropathy. Chinese Journal of Practical Internal Medicine, (12): 551-553 https://doi.org/10.19538/j.nk2019060116
Decroli, E. (2019). Diabetes melitus tipe 2. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas, 1-52.
Feng D. (2020). Phosphorylation of key podocyte proteins and the association with proteinuric kidney disease. American Journal of Physiology. Renal physiology, 319(2), F284–F291. https://doi.org/10.1152/ajprenal.00002.2020
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. International journal of molecular sciences, 21(17), 6275. https://doi.org/10.3390/ijms21176275
Gluhovschi, C., Gluhovschi, G., Petrica, L., Timar, R., Velciov, S., Ionita, I., Kaycsa, A., & Timar, B. (2016). Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy. Journal of diabetes research, 2016, 4626125. https://doi.org/10.1155/2016/4626125
Hara, M., Yamagata, K., Tomino, Y., Saito, A., Hirayama, Y., Ogasawara, S., Kurosawa, H., Sekine, S., & Yan, K. (2012). Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia, 55(11), 2913–2919. https://doi.org/10.1007/s00125-012-2661-7
Jana S, Mitra P, Roy S. Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review. Diseases. 2022; 11. https://doi.org/10.3390/diseases11010008
Kwon, S. K., Kim, S. J., & Kim, H. Y. (2016). Urine synaptopodin excretion is an important marker of glomerular disease progression. The Korean Journal of internal medicine, 31(5), 938–943. https://doi.org/10.3904/kjim.2015.226
Mukherjee, B. (2018). Diabetes and Obesity International Journal Podocyturia-A Reliable Marker for Early Diabetic Nephropathy Diabetes Obes Int J Podocyturia-A Reliable Marker for Early Diabetic Nephropathy. Diabetes & Obesity International Journal. https://doi.org/10.23880/doij-16000186
Politano, S. A., Colbert, G. B., & Hamiduzzaman, N. (2020). Nephrotic Syndrome. Primary care, 47(4), 597–613. https://doi.org/10.1016/j.pop.2020.08.002
Pusat Data dan Informasi. (2018). Hari Diabetes Sedunia. Jakarta. Kementerian Kesehatan RI. Website access on January, 2023. Available from https://pusdatin.kemkes.go.id/article/view/19041500002/haridiabetes-sedunia-2018.html
Samsu, N. (2018). Patogenesis Penyakit Ginjal Diabetik. UB Press. Malang
Sanchez-Niño, M. D., Perez-Gomez, M. V., Valiño-Rivas, L., Torra, R., & Ortiz, A. (2018). Podocyturia: Why it may have added value in rare diseases. Clinical kidney journal, 12(1), 49–52. https://doi.org/10.1093/ckj/sfy081
Sloan L. A. (2019). Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of Diabetes, 11(12), 938–948. https://doi.org/10.1111/1753-0407.12969
Wang, G., Lai, F. M., Lai, K. B., Chow, K. M., Li, K. T., & Szeto, C. C. (2007). Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron. Clinical practice, 106(4), c169–c179. https://doi.org/10.1159/000104428
Zhang, J., Liu, J., & Qin, X. (2018). Advances in early biomarkers of diabetic nephropathy. Revista da Associacao Medica Brasileira (1992), 64(1), 85–92. https://doi.org/10.1590/1806-9282.64.01.85
Zhang, X. X., Kong, J., & Yun, K. (2020). Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies. Journal of diabetes research, 2020, 2315607. https://doi.org/10.1155/2020/2315607
How to Cite
Copyright (c) 2023 Afni Juhairia Laisouw, Liong Boy Kurniawan, Yuyun Widaningsih, Tenri Esa, Himawan Sanusi, Andi Alfian Zainuddin, Theosobia Grace Orno
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.